DUBLIN, April 6, 2022 /PRNewswire/ -- The "Cancer Immunotherapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global cancer immunotherapy market reached a value of US$ 96.6 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 167.5 Billion by 2027 exhibiting a CAGR of 9.10% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Cancer is a preventable disease starting in any organ or tissue of the body on account of the abnormal cell growth that invades adjoining parts of the body and spreads to other organs. It is one of the leading causes of death globally, which is nowadays treated using cancer immunotherapy. Cancer immunotherapy offers more advantages than conventional anti-tumor therapy that can prolong progression-free survival (PFS) and overall survival (OS). It can be combined with radiation, chemotherapy, surgery, or targeted therapies to improve their effectiveness. Apart from this, as it enables the immune system to recognize, prevent, control, and eliminate cancer, cancer immunotherapy finds extensive applications in hospitals, cancer research centers, and clinics around the world.
There is currently an increase in the number of people who have cancer across the globe. This, in confluence with the burgeoning healthcare industry, represents one of the key factors propelling the growth of the market. Moreover, there are fewer side effects associated with cancer immunotherapy. As a result, there is a significant rise in the use of monoclonal antibodies to treat different types of cancer by selectively attacking cancerous cells.
This, coupled with the rising prevalence of multiple myeloma and melanoma, is catalyzing the demand for cancer immunotherapy. Besides this, leading players are sponsoring patient assistance programs (PAPs) that provide financial assistance to low-income individuals for augmenting the existing prescription drug coverage. This, in turn, is positively influencing the market. Other factors strengthening the growth of the market are technological advancements in clinical therapies, extensive research and development (R&D) activities, and the introduction of advanced variants with enhanced efficacy and effectiveness of treatment.
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck KGAA, Novartis AG, Pfizer Inc., Sanofi, and Seagen Inc.
Key Questions Answered in This Report:
- How has the global cancer immunotherapy market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global cancer immunotherapy market?
- What are the key regional markets?
- What is the breakup of the market based on the therapy type?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global cancer immunotherapy market and who are the key players?
- What is the degree of competition in the industry?
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Cancer Immunotherapy Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Therapy Type
6.1 Monoclonal Antibodies
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Cancer Vaccines
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Checkpoint Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Immunomodulators
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Application
7.1 Lung Cancer
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Breast Cancer
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Colorectal Cancer
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Melanoma
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Prostate Cancer
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Head and Neck Cancer
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Others
7.7.1 Market Trends
7.7.2 Market Forecast
8 Market Breakup by End User
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Cancer Research Centers
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Clinics
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
10 SWOT Analysis
11 Value Chain Analysis
12 Porters Five Forces Analysis
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Amgen Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 AstraZeneca plc
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Bayer AG
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Bristol-Myers Squibb Company
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Eli Lilly and Company
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 F. Hoffmann-La Roche AG
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 SWOT Analysis
14.3.7 GlaxoSmithKline Plc
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Johnson & Johnson
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Merck KGAA
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Novartis AG
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 Pfizer Inc.
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.11.4 SWOT Analysis
14.3.12 Sanofi
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
14.3.12.3 Financials
14.3.12.4 SWOT Analysis
14.3.13 Seagen Inc.
14.3.13.1 Company Overview
14.3.13.2 Product Portfolio
14.3.13.3 Financials
14.3.13.4 SWOT Analysis
For more information about this report visit https://www.researchandmarkets.com/r/a6krj5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article